Join to View Full Profile
2013 Jefferson St SWFl 2Roanoke, VA 24014
Phone+1 540-586-5770
Fax+1 540-586-3552
Dr. Kochenderfer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1999 - 2002
West Virginia University School of MedicineClass of 1999
Certifications & Licensure
VA State Medical License 2008 - 2028
NC State Medical License 1999 - 2009
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2013-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2013-2017
Clinical Trials
- Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Start of enrollment: 2021 May 07
Publications & Presentations
PubMed
- Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges.Colin Burns, Ian Muir, Jennifer Foster, Anthony Emanuel, Mark Kochenderfer
Frontiers in Oncology. 2025-01-01 - 47 citationsModified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino
Journal for Immunotherapy of Cancer. 2024-03-13 - 78 citationsOpen-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov
Journal of Clinical Oncology. 2021-03-20
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
